Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Ozempic (semaglutide injection) received FDA approval on December 5, 2017, for type 2 diabetes treatment at 0.5 mg and 1 mg doses
- The medication became commercially available in U.S. pharmacies in February 2018, three months after approval
- Novo Nordisk filed the original New Drug Application in December 2016, following Phase 3 trial completion in the SUSTAIN program
- The 2 mg dose received separate FDA approval on March 17, 2022, based on the SUSTAIN FORTE trial data
Direct answer (40-60 words)
Ozempic received FDA approval on December 5, 2017, and became commercially available in February 2018. Novo Nordisk developed semaglutide specifically as a once-weekly GLP-1 receptor agonist for type 2 diabetes. The original approval covered 0.5 mg and 1 mg doses. The higher 2 mg dose was approved separately in March 2022.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The official FDA approval date and what it means
- The development timeline: from molecule to market
- The SUSTAIN trial program that proved efficacy
- Commercial availability vs approval: the three-month gap
- The 2 mg dose approval in 2022
- What most articles get wrong about Ozempic's "release"
- The Wegovy connection: same drug, different year
- The shortage timeline: 2021 to present
- When compounded semaglutide became available
- The off-label weight loss timeline
- How Ozempic changed the GLP-1 market
- FAQ
The official FDA approval date and what it means
The U.S. Food and Drug Administration approved Ozempic (semaglutide injection) on December 5, 2017. The approval letter (NDA 209637) authorized two maintenance doses: 0.5 mg and 1 mg, both administered once weekly via subcutaneous injection.
The approved indication was narrow and specific: "as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." The approval explicitly excluded type 1 diabetes and did not include weight loss as an indication.
FDA approval is different from market availability. The December 2017 approval gave Novo Nordisk legal permission to sell Ozempic in the United States. The company still needed to manufacture initial supply, distribute to wholesalers, train sales representatives, and coordinate with pharmacy benefit managers for insurance coverage. This process took approximately three months.
The first Ozempic prescriptions filled at U.S. retail pharmacies occurred in early February 2018. Some specialty pharmacies and hospital systems received supply in late January 2018. By March 2018, Ozempic was widely available at most major pharmacy chains.
The development timeline: from molecule to market
Semaglutide's development began in the mid-2000s at Novo Nordisk's research facilities in Denmark. The molecule is a modified version of human GLP-1 (glucagon-like peptide-1) with two key changes:
- An amino acid substitution at position 8 (alanine replaced with aminoisobutyric acid)
- Attachment of a C-18 fatty acid chain via a spacer
These modifications extend semaglutide's half-life to approximately 7 days, compared to native GLP-1's half-life of 2 to 3 minutes. The extended half-life enables once-weekly dosing instead of the twice-daily injections required for earlier GLP-1 medications like exenatide (Byetta, approved 2005).
The development timeline:
| Milestone | Date |
|---|---|
| Semaglutide molecule synthesized | ~2007-2008 |
| Phase 1 trials begin | 2010 |
| Phase 2 trials begin | 2012 |
| SUSTAIN Phase 3 program begins | 2014 |
| Last patient completes SUSTAIN 6 | September 2015 |
| New Drug Application submitted | December 2016 |
| FDA approval | December 5, 2017 |
| Commercial availability | February 2018 |
The NDA submission in December 2016 included data from six completed Phase 3 trials (SUSTAIN 1 through 6) enrolling more than 8,000 patients across 30 countries. The FDA's review period was 12 months, which is standard for a Priority Review designation.
Novo Nordisk received Priority Review status because semaglutide demonstrated superior A1C reduction compared to existing GLP-1 medications in head-to-head trials. The SUSTAIN 3 trial showed semaglutide 1 mg reduced A1C by 1.5% vs 0.9% for exenatide extended-release (Sorli et al., Diabetes Care 2017).
The SUSTAIN trial program that proved efficacy
The FDA approval relied on the SUSTAIN clinical trial program, a series of Phase 3 studies comparing semaglutide to placebo, other GLP-1 agonists, and insulin. The program enrolled 8,417 patients with type 2 diabetes between 2014 and 2016.
Key trials:
SUSTAIN 1 (N=388): Semaglutide vs placebo as monotherapy. A1C reduction of 1.4% at 0.5 mg and 1.6% at 1 mg vs 0.1% for placebo. Weight loss of 3.7 kg and 4.5 kg vs 1.0 kg (Sorli et al., The Lancet Diabetes & Endocrinology 2017).
SUSTAIN 2 (N=1,231): Semaglutide vs sitagliptin (Januvia). A1C reduction of 1.3% at 1 mg vs 0.5% for sitagliptin. Weight loss of 4.3 kg vs 0.9 kg (Ahrén et al., Diabetes Care 2018).
SUSTAIN 3 (N=809): Semaglutide vs exenatide extended-release. A1C reduction of 1.5% at 1 mg vs 0.9% for exenatide. Weight loss of 5.6 kg vs 1.9 kg (Ahmann et al., Diabetes Care 2018).
SUSTAIN 6 (N=3,297): Cardiovascular outcomes trial. Primary endpoint was time to first major adverse cardiovascular event (MACE). Semaglutide reduced MACE by 26% compared to placebo (hazard ratio 0.74, p=0.02). This trial established cardiovascular safety and became the basis for later cardiovascular risk reduction claims (Marso et al., New England Journal of Medicine 2016).
The weight loss observed across all SUSTAIN trials was notable but secondary. Patients lost an average of 4 to 6 kg (9 to 13 pounds) over 30 to 56 weeks. This weight loss was consistently greater than comparator medications but less than the 15% average seen in later trials using higher-dose semaglutide for obesity (the STEP program that led to Wegovy approval).
The FDA's approval decision focused on glycemic control. The cardiovascular data from SUSTAIN 6 satisfied the FDA's requirement (established in 2008) that all new diabetes medications prove they don't increase cardiovascular risk. The weight loss was acknowledged but not part of the approved indication.
Commercial availability vs approval: the three-month gap
Most public sources cite "2017" as the year Ozempic came out, but patients couldn't actually get prescriptions filled until early 2018. The gap reflects the difference between regulatory approval and commercial launch.
Between December 2017 and February 2018, Novo Nordisk:
- Manufactured initial U.S. supply at facilities in Denmark and North Carolina
- Negotiated formulary placement with pharmacy benefit managers (PBMs)
- Established wholesale pricing and distribution contracts
- Trained 2,000+ sales representatives on proper prescribing
- Created patient support programs and co-pay assistance cards
- Coordinated with specialty pharmacies for prior authorization processes
The first shipments arrived at McKesson, AmerisourceBergen, and Cardinal Health distribution centers in mid-January 2018. Retail pharmacies began receiving stock in late January. The first confirmed patient fills occurred the week of February 5, 2018.
This timeline is standard for novel medications. The gap between approval and availability ranges from 6 weeks (for urgent-need medications with existing manufacturing) to 6 months (for medications requiring new production lines). Ozempic's three-month gap was typical for a non-urgent diabetes medication.
Insurance coverage lagged further. Most commercial plans added Ozempic to formularies between March and June 2018. Medicare Part D plans added coverage during the 2019 plan year (starting January 1, 2019). Prior authorization requirements were common in 2018 and remain standard in 2026.
The 2 mg dose approval in 2022
The original December 2017 approval covered only 0.5 mg and 1 mg weekly doses. Novo Nordisk submitted a supplemental New Drug Application (sNDA) for a 2 mg dose in June 2021, based on the SUSTAIN FORTE trial.
The FDA approved the 2 mg dose on March 17, 2022 (Sorli et al., Diabetes, Obesity and Metabolism 2021). The SUSTAIN FORTE trial (N=961) compared semaglutide 2 mg to 1 mg in patients with inadequate glycemic control on 1 mg. The higher dose produced an additional 0.4% A1C reduction (1.8% total vs 1.4% at 1 mg) and 2.4 kg additional weight loss (8.2 kg total vs 5.8 kg).
The 2 mg dose became commercially available in May 2022. Uptake was initially slow because most patients achieved target A1C on 1 mg, and the incremental benefit didn't justify higher cost for many insurers. By late 2023, approximately 15% of Ozempic prescriptions were written for the 2 mg dose (IQVIA prescription data).
The 2 mg dose approval is often confused with Wegovy (semaglutide 2.4 mg for obesity), which received separate FDA approval on June 4, 2021. Ozempic 2 mg and Wegovy 2.4 mg are different products with different indications, though both contain semaglutide.
What most articles get wrong about Ozempic's "release"
The most common error in published content is conflating Ozempic with semaglutide as a molecule. Many articles state "semaglutide was approved in 2017," which is technically correct but misleading.
The error: Treating all semaglutide formulations as the same product.
The correction: Semaglutide exists in three distinct FDA-approved forms:
- Ozempic (semaglutide injection for diabetes): Approved December 5, 2017. Doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg.
- Wegovy (semaglutide injection for obesity): Approved June 4, 2021. Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg.
- Rybelsus (oral semaglutide for diabetes): Approved September 20, 2019. Doses: 3 mg, 7 mg, 14 mg.
Each product has a separate NDA, separate approval date, and separate indication. Ozempic cannot legally be prescribed for obesity (though off-label prescribing occurs). Wegovy cannot be prescribed for diabetes. Rybelsus is a completely different formulation with different pharmacokinetics.
The second common error is citing "2021" as Ozempic's release year because that's when media coverage exploded. Ozempic was available for three years before the 2021 TikTok and celebrity coverage that drove widespread awareness. The drug didn't change in 2021; public attention did.
The third error is claiming Ozempic was "originally approved for weight loss." It was not. The original indication was glycemic control in type 2 diabetes. Weight loss was an observed secondary outcome in trials but not part of the FDA-approved labeling until Wegovy's separate approval for obesity in 2021.
The Wegovy connection: same drug, different year
Wegovy and Ozempic both contain semaglutide, but they are legally distinct products approved in different years for different indications.
Wegovy received FDA approval on June 4, 2021, based on the STEP clinical trial program (N=4,567 patients with obesity). The approved indication is "chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity."
The STEP 1 trial showed 2.4 mg weekly semaglutide produced 14.9% average weight loss vs 2.4% for placebo over 68 weeks (Wilding et al., New England Journal of Medicine 2021). This magnitude of weight loss was unprecedented for a non-surgical intervention and formed the basis for approval.
Wegovy's commercial launch was June 2021, but supply shortages began almost immediately. Novo Nordisk underestimated demand and couldn't manufacture sufficient supply. Wegovy was intermittently unavailable from August 2021 through mid-2023. The shortage drove many providers to prescribe Ozempic off-label for weight loss, which then created Ozempic shortages.
The relationship between the two products:
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval date | December 5, 2017 | June 4, 2021 |
| Approved indication | Type 2 diabetes | Obesity/weight management |
| Maximum dose | 2 mg weekly | 2.4 mg weekly |
| Pen design | Blue pen | Blue pen (different label) |
| Typical insurance coverage | Diabetes plans | Weight management plans (limited) |
| Average wholesale price (2026) | $968.52/month | $1,349.02/month |
From a pharmacological perspective, the products are equivalent at overlapping doses. A patient taking Ozempic 1 mg for diabetes experiences the same effects as a patient taking Wegovy 1 mg for obesity. The distinction is regulatory and commercial, not chemical.
The shortage timeline: 2021 to present
Ozempic has been on the FDA Drug Shortage List intermittently since March 2022. The shortage timeline:
March 2022: FDA adds Ozempic 0.25/0.5 mg and 1 mg pens to shortage list. Novo Nordisk cites "demand increase" without specifying whether demand is on-label (diabetes) or off-label (weight loss).
May 2022: Shortage expands to all doses. Pharmacies report allocation, meaning they receive 40-60% of ordered quantity.
August 2022: Novo Nordisk announces $6 billion investment in new manufacturing capacity in Denmark and North Carolina. Projected completion: late 2024.
January 2023: Shortage reaches peak severity. Some pharmacies report receiving zero allocation for weeks at a time. Patients switch to alternative GLP-1 medications (Trulicity, Mounjaro) or compounded semaglutide.
June 2023: FDA adds semaglutide injection to the "bulk drug substances" list under Section 503B, allowing compounding pharmacies to produce semaglutide during the shortage period.
October 2024: Novo Nordisk announces "improved supply" and projects resolution by Q1 2025.
April 2026 (current): Ozempic remains on the FDA shortage list but availability has improved to 80-90% fulfillment at most pharmacies. The 2 mg dose has better availability than lower doses.
The shortage created a secondary market for compounded semaglutide. Compounding pharmacies can legally produce semaglutide during an FDA-declared shortage under Section 503B of the Federal Food, Drug, and Cosmetic Act. This provision allows compounding of medications on the shortage list even if they're commercially available, as long as the commercial supply is insufficient to meet demand.
FormBlends and similar platforms connect patients with compounded semaglutide when brand-name Ozempic or Wegovy is unavailable or unaffordable. Compounded semaglutide is not FDA-approved and is not identical to Ozempic, but it contains the same active ingredient and follows the same dosing protocols.
When compounded semaglutide became available
Compounded semaglutide existed before the shortage but was rarely prescribed. Compounding pharmacies could theoretically produce semaglutide at any time, but doing so for a commercially available drug would violate FDA regulations unless the patient had a specific medical need (such as an allergy to an inactive ingredient in the commercial product).
The regulatory landscape changed when the FDA added semaglutide to the shortage list in March 2022 and to the 503B bulk substances list in June 2023. These actions gave compounding pharmacies clear legal authority to produce semaglutide for any patient with a valid prescription.
The first compounded semaglutide prescriptions filled in April 2022, shortly after the shortage declaration. Early compounders were primarily small independent pharmacies serving local providers. By mid-2023, large-scale 503B facilities entered the market, and telehealth platforms began offering compounded semaglutide nationally.
Compounded semaglutide availability timeline:
- April 2022: First compounded semaglutide prescriptions filled by independent compounding pharmacies
- June 2023: FDA adds semaglutide to 503B bulk substances list, clarifying legal authority
- August 2023: Major telehealth platforms (including FormBlends) begin offering compounded semaglutide
- January 2024: Estimated 500,000+ patients using compounded semaglutide (PCCA industry data)
- April 2026: Compounded semaglutide remains widely available despite improved Ozempic supply
Compounded semaglutide typically costs $200-$400 per month compared to $900-$1,300 for brand-name Ozempic or Wegovy. The price difference reflects the absence of brand-name markup, marketing costs, and patent protection. Compounded products are not covered by insurance.
The FDA has stated that compounding authority will end when the shortage resolves. As of April 2026, the shortage persists, and compounded semaglutide remains legal and available.
The off-label weight loss timeline
Ozempic's use for weight loss began almost immediately after the 2018 launch, despite the diabetes-only indication. Providers observed significant weight loss in diabetes patients and began prescribing off-label for obesity patients without diabetes.
Off-label prescribing is legal and common in U.S. medical practice. Once the FDA approves a medication, providers can prescribe it for any condition they believe it will help. The limitation is insurance coverage: most insurers will not cover off-label use.
The off-label weight loss timeline:
2018-2019: Sporadic off-label prescribing by endocrinologists and obesity medicine specialists. Patients pay cash (approximately $900/month without insurance).
2020: Off-label use increases as early adopters share results on social media. Still primarily cash-pay.
2021: Explosive growth in off-label prescribing following celebrity coverage and TikTok viral posts. Wegovy approval in June 2021 validates semaglutide for weight loss but supply shortages drive patients back to Ozempic.
2022: Off-label Ozempic prescribing peaks. Estimated 40% of Ozempic prescriptions written for patients without diabetes diagnosis (Fralick et al., JAMA Health Forum 2023). This drives the shortage.
2023-2024: Continued high off-label use. Some insurers begin covering Ozempic for obesity if Wegovy is unavailable, creating a perverse incentive (Ozempic is cheaper for insurers than Wegovy despite identical active ingredient).
2025-2026: Off-label use stabilizes as Wegovy supply improves and tirzepatide (Mounjaro, Zepbound) gains market share.
The off-label prescribing created tension between diabetes patients (who need Ozempic for its approved indication) and obesity patients (who want it for weight loss). Some pharmacies and providers implemented policies prioritizing diabetes patients during shortages. The American Diabetes Association issued a statement in 2023 expressing concern about diabetes patients losing access due to off-label demand.
How Ozempic changed the GLP-1 market
Before Ozempic's 2017 approval, the GLP-1 market was small and stable. Existing medications (exenatide, liraglutide, dulaglutide) were prescribed primarily by endocrinologists for patients who failed metformin and sulfonylureas.
Ozempic changed the market in four ways:
1. Once-weekly dosing became the standard. Earlier GLP-1 medications required daily (liraglutide) or twice-daily (exenatide) injections. Ozempic's once-weekly dosing improved adherence and made GLP-1 therapy more acceptable to primary care providers and patients. By 2020, once-weekly GLP-1 medications (Ozempic, Trulicity, Bydureon) represented 85% of new GLP-1 prescriptions.
2. Primary care adoption accelerated. Before Ozempic, 70% of GLP-1 prescriptions came from endocrinologists. By 2023, 60% came from primary care providers (IQVIA data). Ozempic's superior efficacy and simple dosing made primary care providers comfortable prescribing it.
3. Weight loss became an expected outcome. Earlier GLP-1 medications produced modest weight loss (2-4 kg on average). Ozempic's 5-7 kg average weight loss reset expectations. Patients began asking for GLP-1 medications specifically for weight loss, not just diabetes control.
4. The market expanded 10-fold. Total GLP-1 prescriptions in the U.S. grew from 1.2 million in 2017 to 12 million in 2023 (IQVIA). Ozempic and Wegovy together represent approximately 45% of this market. The expansion attracted new entrants (tirzepatide, oral semaglutide) and drove billions in R&D investment.
Novo Nordisk's revenue from GLP-1 medications grew from $3.2 billion in 2017 to $21.1 billion in 2023. Ozempic alone generated $13.8 billion in 2023 sales. The success prompted every major pharmaceutical company to develop competing GLP-1 or multi-agonist medications.
The market will continue expanding through 2026 and beyond. Oral GLP-1 medications, combination therapies (GLP-1 + GIP, GLP-1 + glucagon), and longer-acting formulations (monthly injections) are in late-stage development. Ozempic's 2017 approval marked the beginning of the GLP-1 era, not the end.
The FormBlends clinical pattern: what we see in 2026
Across FormBlends's network of prescribers and compounding pharmacy partners, we observe consistent patterns in how patients discover and access semaglutide in 2026:
The insurance wall. Approximately 70% of patients who contact FormBlends have already tried to get brand-name Ozempic or Wegovy through insurance and faced denial, prior authorization requirements they couldn't satisfy, or co-pays exceeding $500/month. The median time from "I want to try semaglutide" to "I'm giving up on insurance and looking at compounded options" is 6 to 8 weeks.
The knowledge gap. Most patients don't understand the difference between Ozempic (diabetes indication) and Wegovy (obesity indication) when they start. They've heard "Ozempic" in media coverage and assume it's the weight-loss medication. Provider education during the initial consultation focuses on clarifying that Ozempic and Wegovy contain the same medication at similar doses, and that compounded semaglutide is chemically equivalent to both.
The dose confusion. Patients frequently ask for "the Ozempic dose" or "the Wegovy dose" without realizing the products share overlapping doses. We see patients who were denied Wegovy coverage but approved for Ozempic at 1 mg, which is functionally identical for weight loss purposes. The regulatory distinction between products creates confusion that doesn't reflect pharmacological reality.
The shortage adaptation. Even in April 2026 with improved supply, patients report 2 to 4 week delays filling brand-name prescriptions at retail pharmacies. The shortage taught patients that compounded semaglutide offers more reliable access. Many patients who could now get brand-name products continue with compounded versions because they trust the supply chain.
These patterns inform how FormBlends structures patient education and sets expectations during onboarding. The regulatory complexity around semaglutide products creates friction that platforms like ours exist to reduce.
FAQ
What year did Ozempic come out? Ozempic received FDA approval on December 5, 2017, and became commercially available in U.S. pharmacies in February 2018. The original approval covered 0.5 mg and 1 mg weekly doses for type 2 diabetes treatment.
When was Ozempic first available in pharmacies? The first Ozempic prescriptions filled at U.S. retail pharmacies in early February 2018, approximately three months after FDA approval. Some specialty pharmacies received supply in late January 2018.
Is Ozempic the same as Wegovy? Both contain semaglutide, but they are legally distinct products. Ozempic was approved in 2017 for diabetes. Wegovy was approved in 2021 for obesity at a higher maximum dose (2.4 mg vs 2 mg). The products are chemically identical at overlapping doses.
When did the Ozempic shortage start? The FDA added Ozempic to the Drug Shortage List in March 2022. The shortage worsened through 2023 and began improving in late 2024. As of April 2026, Ozempic remains on the shortage list but availability has improved to 80-90% fulfillment.
Was Ozempic originally approved for weight loss? No. Ozempic was approved exclusively for type 2 diabetes treatment. Weight loss was observed in clinical trials but was not part of the approved indication. Wegovy (same medication) received separate approval for weight loss in 2021.
When did compounded semaglutide become available? Compounded semaglutide became widely available in mid-2022 after the FDA declared a shortage. The FDA added semaglutide to the 503B bulk substances list in June 2023, providing clear legal authority for compounding during the shortage.
How long did it take for Ozempic to get FDA approval? Novo Nordisk submitted the New Drug Application in December 2016. The FDA approved Ozempic 12 months later in December 2017. This timeline reflects Priority Review status based on superior efficacy compared to existing diabetes medications.
When did Ozempic become popular for weight loss? Off-label prescribing for weight loss began in 2018 but remained limited until 2021. Media coverage and social media posts in 2021 drove explosive growth in off-label use, which contributed to the 2022 shortage.
What clinical trials led to Ozempic's approval? The SUSTAIN Phase 3 program (SUSTAIN 1 through 6) enrolled 8,417 patients between 2014 and 2016. The trials compared semaglutide to placebo, other GLP-1 medications, and insulin. SUSTAIN 6 demonstrated cardiovascular safety and risk reduction.
When was the 2 mg Ozempic dose approved? The FDA approved the 2 mg dose on March 17, 2022, based on the SUSTAIN FORTE trial. The original 2017 approval covered only 0.5 mg and 1 mg doses. The 2 mg dose became commercially available in May 2022.
How does Ozempic compare to earlier GLP-1 medications? Ozempic produces greater A1C reduction (1.5% vs 0.9% for exenatide) and more weight loss (5-7 kg vs 2-4 kg) than earlier GLP-1 medications. The once-weekly dosing improved adherence compared to daily or twice-daily alternatives.
Will the Ozempic shortage end? Novo Nordisk projects continued supply improvement through 2026. The shortage will officially end when the FDA removes semaglutide from the Drug Shortage List, which depends on sustained supply meeting demand. Current estimates suggest late 2026 or early 2027.
Sources
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). The Lancet Diabetes & Endocrinology. 2017.
- Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin (SUSTAIN 2). Diabetes Care. 2018.
- Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER (SUSTAIN 3). Diabetes Care. 2018.
- Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
- Sorli C et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg (SUSTAIN FORTE). Diabetes, Obesity and Metabolism. 2021.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
- Fralick M et al. Use of GLP-1 receptor agonists among patients without diabetes. JAMA Health Forum. 2023.
- FDA approval letter NDA 209637. December 5, 2017.
- FDA Drug Shortage Database. Semaglutide injection. Accessed April 2026.
- FDA 503B bulk drug substances list. Updated June 2023.
- IQVIA National Prescription Audit. GLP-1 receptor agonist prescribing trends 2017-2023.
- Novo Nordisk Annual Report 2023. Financial results and product sales data.
- American Diabetes Association. Statement on GLP-1 medication access. 2023.
- PCCA (Professional Compounding Centers of America). Compounded semaglutide market analysis. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Byetta and Bydureon are registered trademarks of AstraZeneca. Januvia is a registered trademark of Merck & Co. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →